Extranodal Natural Killer/T-Cell Lymphoma: A Rare Nasal-Type Case

Nasal type extranodal natural killer (NK) NK-cell/T-cell lymphoma (NKTCL) is a rare extranodal lymphoma of NK-cell or T-cell origin that most commonly affects immunocompetent middle-aged men of Asian or Native American descent [1]. The pathogenesis is not understood completely, but it is related in part to infection of the tumor cells with Epstein-Barr virus (EBV) [2]. Around 6-7% of all non-Hodgkin’s lymphoma (NHL) in Southeast Asia accounts for NKTCL. However, the incidence of NHL is lower in the United States at 1.5% [3,4]. Disease within the nasal cavity has a better prognosis. Radiation therapy alone can be curative. Over 60% of patients with stage 1 disease remain in long-term remission following treatment with radiation therapy with or without chemotherapy [5]. Nasal disease may be cured with radiotherapy at a rate of 85%. However, the relapse rate is high at 25%. Therefore, it is highly crucial for this aggressive disease to be diagnosed and treated at an early stag

An unusual case of CD5 negative Mantle cell lymphoma presenting with IgM monoclonal gammopathy

albayrak, murat/0000-0003-4025-741X; Onec, Birgul/0000-0003-2824-1044WOS: 000385138900009

CLL Case With Skin Involvement

Kronik lenfositik lösemi, kronik lenfoproliferatif hastalıklardan birisidir. KLL, monoklonal olan işlevsel olarak yetersiz lenfositlerin progresif birikimiyle karakterizedir. KLL hücreleri herhangi bir organa infiltre olabilir ama tanı anında cilt (leukemia cutis), en yaygın olarak infiltre olan non-lenfoid organdır. KLL tanısı olup cilt tutulumuyla prezente olan bir olgu sunulmuştur.Chronic lymphocytic leukemia is one of the chronic lymphoproliferative disorders. CLL is characterized by monoclonal functionally-inefficient lymphocytes accumulation. Chronic lymphocytic leukemia cells can infiltrate any organ, but skin is the most commonly infiltrated non-lymphoid organ at the diagnosis (leukemia cutis). Our case is Chronic Lymphocytic Leukemia, case is presented with skin involvement

The Predictive Role of the Neutrophil/Lymphocyte Ratio in Survival with Multiple Myeloma: A Single Center Experience

albayrak, murat/0000-0003-4025-741X; Onec, Birgul/0000-0003-2824-1044WOS: 000397489300008PubMed: 27500465BackgroundRecent studies have shown a positive correlation between tumor-related immune response markers and the poor outcome in solid tumors. In this study, we aimed to investigate the neutrophil/lymphocyte ratio (NLR) in multiple myeloma. To the best of our knowledge, this would be the second report concerning this topic. MethodsWe retrospectively reviewed the data for 52 multiple myeloma patients. The patients were grouped using the baseline NLR as NLR 1.72 and NLR > 1.72 using receiver operating characteristic analysis to determine a cut off. We compared the two groups in terms of both the known prognostic factors of the myeloma and the overall survival (OS). ResultsOur study showed that NLR is associated with C-reactive protein and 2 microglobulin (P = 0.02 and P = 0.001, respectively). The patients with NLR > 1.72 had significantly worse stages, performance status, and kidney functions. The whole group's OS was estimated as 35.1 months while the patients with lower NLR had better OS when compared with those with NLR > 1.72 (42.75 and 26.14 months, respectively, P: 0.04). ConclusionNeutrophil/lymphocyte ratio, which is associated with stage, performance status, and kidney functions, can be used in daily practice as a predictor for survival in multiple myeloma. Simply adding NLR to the routine charts may enrich our data for larger studies

Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population

albayrak, murat/0000-0003-4025-741XWOS: 000386685400009PubMed: 27812251Multiple myeloma (MM) is a disease of the geriatric population with a median age at diagnosis of 69 years but most clinicians consider performance status and comorbidities rather than chronological age in determining prognosis and treatment. The purpose of this study was to assess whether and which comorbidity indices predict survival in a real life population of MM. We calculated Charlson Comorbidity Index (CCI), age combined Charlson index (CCI-age), Hematopoietic cell transplantation-specific comorbidity index (HCT-SCI) and Freiburger comorbidity index (FCI) retrospectively for 66 MM patients and compared their impact on treatment responses and overall survival (OS). Treatment response was significantly worse in groups with high CCI, CCI-age, HCT-SCI scales (p < 0.05), but FCI's effect on treatment response was not significant. However, while no significant relationship was determined between other comorbidity indices with OS, it was related only with FCI-CI (p = 0.006). FCI, developed in this patient group, was the only prognostic index with a significant effect on OS in the evaluation of comorbidities in MM patients with different scores, but its relationship to treatment responses was not significant contrary to other indices. While this small patient group gave us hope regarding the use of FCI in practice, multi-center studies are still required

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)

Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival